OBJECTIVES: The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA. METHODS: We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100,000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. RESULTS: Survival for HIV-infected women who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100,000 exposed women, compared with 72.46/100,000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. CONCLUSIONS: Use of non-efavirenz-based initial ART in HIV-infected women of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.
OBJECTIVES: The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infectedwomen of childbearing age in the USA. METHODS: We used data from the Women's Interagency HIV Study in an HIV disease simulation model to estimate life expectancy in women who receive an efavirenz-based initial antiretroviral regimen compared with those who delay efavirenz use and receive a boosted protease inhibitor-based initial regimen. To estimate excess risk of teratogenic events with and without efavirenz exposure per 100,000 women, we incorporated literature-based rates of pregnancy, live births, and teratogenic events into a decision analytic model. We assumed a teratogenicity risk of 2.90 events/100 live births in women exposed to efavirenz during pregnancy and 2.68/100 live births in unexposed women. RESULTS: Survival for HIV-infectedwomen who received an efavirenz-based initial antiretroviral therapy (ART) regimen was 0.89 years greater than for women receiving non-efavirenz-based initial therapy (28.91 vs. 28.02 years). The rate of teratogenic events was 77.26/100,000 exposed women, compared with 72.46/100,000 unexposed women. Survival estimates were sensitive to variations in treatment efficacy and AIDS-related mortality. Estimates of excess teratogenic events were most sensitive to pregnancy rates and number of teratogenic events/100 live births in efavirenz-exposed women. CONCLUSIONS: Use of non-efavirenz-based initial ART in HIV-infectedwomen of childbearing age may reduce life expectancy gains from antiretroviral treatment, but may also prevent teratogenic events. Decision-making regarding efavirenz use presents a trade-off between these two risks; this study can inform discussions between patients and health care providers.
Authors: Antonia L Moore; Ole Kirk; Anne M Johnson; Christine Katlama; Anders Blaxhult; Manfred Dietrich; Robert Colebunders; Antonio Chiesi; Jens D Lungren; Andrew N Phillips Journal: J Acquir Immune Defic Syndr Date: 2003-04-01 Impact factor: 3.731
Authors: L Stewart Massad; Gayle Springer; Lisa Jacobson; Heather Watts; Kathryn Anastos; Abner Korn; Helen Cejtin; Alice Stek; Mary Young; Julie Schmidt; Howard Minkoff Journal: AIDS Date: 2004-01-23 Impact factor: 4.177
Authors: Kathryn Anastos; Yolanda Barrón; Mardge H Cohen; Ruth M Greenblatt; Howard Minkoff; Alexandra Levine; Mary Young; Stephen J Gange Journal: Ann Intern Med Date: 2004-02-17 Impact factor: 25.391
Authors: S D Nightingale; D W Cameron; F M Gordin; P M Sullam; D L Cohn; R E Chaisson; L J Eron; P D Sparti; B Bihari; D L Kaufman Journal: N Engl J Med Date: 1993-09-16 Impact factor: 91.245
Authors: Stephen R Cole; Miguel A Hernán; James M Robins; Kathryn Anastos; Joan Chmiel; Roger Detels; Carolyn Ervin; Joseph Feldman; Ruth Greenblatt; Lawrence Kingsley; Shenghan Lai; Mary Young; Mardge Cohen; Alvaro Muñoz Journal: Am J Epidemiol Date: 2003-10-01 Impact factor: 4.897
Authors: P M Girard; R Landman; C Gaudebout; R Olivares; A G Saimot; P Jelazko; C Gaudebout; A Certain; F Boué; E Bouvet Journal: N Engl J Med Date: 1993-05-27 Impact factor: 91.245
Authors: F van Leth; P Phanuphak; K Ruxrungtham; E Baraldi; S Miller; B Gazzard; P Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; R Wood; G C Levi; G Reboredo; K Squires; I Cassetti; D Petit; F Raffi; C Katlama; R L Murphy; A Horban; J P Dam; E Hassink; R van Leeuwen; P Robinson; F W Wit; J M A Lange Journal: Lancet Date: 2004-04-17 Impact factor: 79.321
Authors: Adolfo Correa-Villaseñor; Janet Cragan; James Kucik; Leslie O'Leary; Csaba Siffel; Laura Williams Journal: Birth Defects Res A Clin Mol Teratol Date: 2003-09
Authors: Susie E Huntington; Loveleen K Bansi; Claire Thorne; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: AIDS Date: 2011-08-24 Impact factor: 4.177
Authors: Ushma Mehta; Christine Clerk; Elizabeth Allen; Mackensie Yore; Esperança Sevene; Jan Singlovic; Max Petzold; Viviana Mangiaterra; Elizabeth Elefant; Frank M Sullivan; Lewis B Holmes; Melba Gomes Journal: BMC Pregnancy Childbirth Date: 2012-09-03 Impact factor: 3.007